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Abstract In 2011, a large outbreak caused by a Shiga toxin
producing E. coli (STEC) occurred in Northern Germany,
with a satellite outbreak in Western France, including the
highest number of hemolytic uremic syndrome (HUS) cases
ever encountered during a STEC outbreak. The outbreak
strain was characterized as an enteroaggregative E. coli of
serotype O104:H4 expressing a phage-encoded Shiga toxin
2. The majority of STEC infections and HUS cases were
observed in adults, with a preponderance of the female gender.
The outbreak imposed huge challenges on clinicians, micro-
biologists, and epidemiologists but also provided important
new insight for the understanding of STEC infection. Thus,
novel therapeutic strategies in the treatment of HUS in adults
and for decolonization of long-term STEC carriers were eval-
uated. This review highlights the unusual features of the recent
O104:H4 outbreak and focuses on emerging new strategies in
diagnostics and treatment of acute STEC-related disease, as
well as STEC long-term carriage.
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Introduction
Shiga toxin (Stx) producing Escherichia coli (STEC) were
first described as Vero toxin producing E. coli (VTEC)
leading to bloody diarrhea (hemorrhagic colitis) and the he-
molytic uremic syndrome (HUS) about 30 years ago [1, 2].
HUS is characterized by hemolytic anemia, thrombocytope-
nia, acute kidney injury (AKI), and, in severe cases, neuro-
logic complications. The natural reservoirs of STEC are
ruminant animals, especially cattle. Transmission to humans
usually occurs via contaminated food or water. Numerous
outbreaks, as well as sporadic cases of STEC infections and
HUS, have been documented worldwide. Obviously, the larg-
est and best documented outbreaks were recorded in industri-
alized countries. This, however, does not necessarily mirror an
increased frequency of STEC infections in developed
countries but, rather, results from a reporting bias due to
diagnostic resources, nationwide reporting systems, and publi-
cation activities [3]. Alternatively, in contrast to locally restrict-
ed farming in developing countries, modern industrialized
large-scale food productionmight serve as a widespread vector
in cases of food contamination.
STEC strains carry phages that encode Shigatoxins 1
and/or 2, also known as Vero toxins or Verocytotoxins [2,
4]. For both Stx 1 and Stx 2, several allelic variants are
described [5]. Enterohemorrhagic E. coli (EHEC), the “clas-
sical” subset of STEC, possess the eae gene of enteropatho-
genic E. coli as an additional virulence factor conferring
adherence to the intestinal mucosa. STEC not harboring eae
were long believed to be less virulent but have also been
shown to be the causative agent of STEC outbreaks [6, 7].
The pathogenesis of HUS development is incompletely
understood [8]. In brief, STEC are incorporated by macro-
phages and M cells of the colon mucosa and produce toxin,
which is released when the host cell undergoes apoptosis.
After local and systemic distribution, Stx causes damage to
vascular endothelial cells of the kidney and brain by direct
cytotoxicity, as well as indirectly via cytokine secretion,
complement activation, and subsequent generalized disease.
E. coli can be subclassified by O and H serotyping. STEC
usually belong to a relatively limited number of O:H
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serotypes. O157:H7 is the serotype that was documented in
the vast majority of HUS cases [9]. However, in some
geographic regions, including Germany, non-O157 sero-
types have been reported to account for up to half of HUS
cases [10, 11].
In Germany, STEC were commonly recognized as
pathogens causing rare but severe disease almost exclu-
sively in younger children. Before 2011, about 1,000
infections per year and fewer than 100 cases of HUS
were registered throughout Germany [12]. This review
focuses on the 2011 outbreak of a STEC of serotype
O104:H4, with unusual genetic properties leading to
atypical epidemiologic and clinical presentation. Its im-
pact on the scientific understanding of STEC is compared
with historical data. New developments in the diagnosis and
treatment of STEC and HUS are highlighted, as well as ques-
tions remaining open.
The Recent German and Major Historical STEC
Outbreaks
STEC primarily cause sporadic disease or small outbreaks
limited to a few individuals. However, most information
about STEC disease and its therapeutic implications was
drawn from larger food-borne outbreaks, because the re-
sponsible strains were usually well characterized and epide-
miological and clinical data were sufficiently available to
gain statistically solid insight.
Northern Germany Outbreak, 2011
The 2011 outbreak of a STEC O104:H4 in Northern Germany
started at the beginning of May, reaching its peak on May 22.
Until July 4, when the end of the outbreak was officially
declared, 855 cases of HUS, 2,987 cases of acute gastroenter-
itis, and 53 deaths were registered in Germany [13, 14•].
Additionally, 83 EHEC cases and 54 cases of HUS were
recorded outside Germany, most of them linked to travel to
Northern Germany in May 2011 [14•]. Fenugreek sprouts
were identified as the most likely vehicle of infection and
were traced back to a single producer [15]. Despite all efforts,
the strain could not be isolated from the implicated seeds.
Shortly after the discovery of sprouts as the source of infec-
tion, a smaller outbreak by STECO104:H4 was reported from
Western France, including 24 patients with 7 cases progress-
ing to HUS [16]. Here again, consumption of Fenugreek
sprouts was associated with infections.
The outbreak proved a major challenge to clinicians,
microbiologists, and epidemiologists, not only because of
its severity, but also due to its unusual presentation. In
contrast to earlier outbreaks, the majority of patients were
adults, predominantly middle-aged and otherwise healthy
women. The incidence rate of HUS (22 %) was higher than
reported in previous outbreaks (1 %–15 %) [17••] and was
accompanied by an unusually high number of cases with
severe neurological symptoms (aphasia, seizures, and delir-
ium) [18]. The incubation time was approximately 8 days
[13], which is longer than the incubation period reported for
STEC O157 during an outbreak in Washington in 1994 [19].
Early during the outbreak, the national HUS reference
center identified the strain as being of serotype O104:H4 and
as belonging to a clone (HUSEC041) originally isolated from
an HUS patient in Germany in 2001 [20•]. Previously, there
were reports of six sporadic cases of HUS caused by a STEC
O104:H4 in Germany, France, Korea, and Georgia; however,
molecular fingerprinting of the available strains revealed them
to be not identical [21]. The 2011 outbreak strain combined
virulence factors of both enteroaggregativeE. coli (EAEC) and
STEC, harboring the pAA plasmid of EAEC, as well as a Stx 2
producing phage, combined with an extended spectrum beta-
lactamase encoding plasmid [20•], and was therefore called an
“enteroaggregative STEC.” Whole genome sequencing was
undertaken, and its results were also available early on during
the outbreak [22–24]. Moreover, a multiplex polymerase chain
reaction PCR assay for the parallel detection of several char-
acteristic virulence factors (stx2, terD, rfbO104, fliC H4) was
rapidly developed and made publicly available [20•].
Despite the observation that the constitutive Stx production
of STEC O104:H4 was lower, as compared with “classical”
O157:H7 strains [25], the proportion of patients developing
HUS was greater than in most outbreaks before. This led to
speculation about a possible hypervirulence of STEC O104:
H4, potentially mediated by a facilitated Stx uptake due to the
very efficient adherence of EAEC to the intestinal mucosa
[26]. While the core genome of STEC O104:H4 is highly
similar to other EAEC of the same serotype, the Stx-phage
was shown to be most closely related to the phage of an O111:
H- strain [25] and has probably been acquired quite recently in
the phylogenetic history of the outbreak strain.
During the outbreak, the mean shedding period was
reported to be more than 34 days for STEC O104:H4 in
patients not receiving antibiotics [27••], with some of them
still shedding the pathogenmore than 1 year after the outbreak
(unpublished data). These data indicate that the outbreak strain
might be carried for longer periods, as compared with STEC
O157, for which a maximal shedding period of 124 days was
reported [28]. This difference might be explained by the enter-
oaggregative adherence to human cells.
Historical Outbreaks With “Classical” STEC O157:H7
There are numerous reports on STEC O157:H7 as the most
common serotype associated with HUS, especially in chil-
dren. The historical outbreak most comparable to the recent
German epidemic was likewise linked to sprouts and took
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place in Japan in 1996 (Sakai city outbreak). About 6,000
persons were affected after white radish sprouts had been
served at school canteens, exposing 47,000 children to the
contaminated food [29, 30]. As compared with the German
outbreak in 2011, the incidence of HUS in the Sakai city
outbreak was considerably lower (106 cases out of 6,000
infections). Also in 1996, another outbreak of a STEC
O157:H7 in Scotland involved 512 persons, of whom 279
cases were microbiologically confirmed. In this outbreak,
the majority of patients developing HUS were adults (28 of
the 34). Contaminated meat products were identified as the
outbreak source [31, 32]. Another massive outbreak of O157:
H7 that gained particular attention happened in the western
U.S. in 1993, comprising 501 cases, 151 hospitalizations, and
45 cases of HUS. This outbreak was linked to consumption of
undercooked hamburger meat at a fast food chain [19] and
promoted the (misleading) opinion that ground beef is the
primary vehicle for STEC infections.
Non-O157 Outbreaks
Several reports on non-O157 STEC underline their potential
to cause sporadic disease as well as epidemics. One of the
largest non-O157 STEC outbreaks was caused by STEC
O111:NM in Oklahoma in 2008 [33]. Out of 341 cases with
gastroenteritis, 71 patients required hospitalization. The
HUS rate was 17 %, and more than 50 % of HUS patients
were adults. In 1992, STEC O111:H2 was isolated from the
stools of 5 out of 10 children hospitalized with HUS and of
3 healthy contact persons in South Picardy, France [34].
Later on, this strain was shown to adhere to epithelial cells
in an aggregative pattern and to possess the EAEC virulence
plasmid [35], while also producing Stx 2. However, this
“intermediate” virulence strain affected only children, and
the outbreak source remained unclear.
EAEC was consistently shown to have the potential of
causing severe gastroenteritis in the absence of Shiga toxins.
The largest EAEC outbreak occurred in Japan in 1993,
when 2,967 children developed severe gastroenteritis after
having consumed the same school lunch. Stools from 30
patients were studied, and 27 strains of an E. coli ONT:H10
were isolated. The strain adhered to epithelial cells in vitro
in the typical aggregative pattern of EAEC but was negative
for all virulence factors of diarrheagenic E. coli, including
Shiga toxins except for the presence of the enteroaggrega-
tive heat-stable toxin.
These and other reports show the high diversity of STEC
strains and the potential of pathogenic E. coli to acquire
virulence factors by horizontal gene transfer, resulting in
new hybrid phenotypes and “atypical” clinical presenta-
tions. This challenges the detection of new STEC strains
and the prediction of their pathogenicity, underlining the need
for further investigation.
New Therapeutic Approaches During the STEC O104:
H4 Outbreak
During the 2011 outbreak in Northern Germany, clinicians
were confronted with a large number of mainly adult
patients with HUS associated with severe hemolysis and
neurological complications [18, 36]. A large proportion of
patients required renal replacement therapy. However, we
also observed some STEC-infected patients with severe
neurological disorders but lacking renal or hematologic
signs of HUS (unpublished data).
Prior to the outbreak, no standardized causative treatment
existed for STEC-HUS, and randomized clinical trials ap-
proving any therapeutic concept to be beneficial beyond
best supportive therapy were missing [37]. Therefore, dif-
ferent therapeutic concepts were rapidly proposed [38] on
the basis of theoretical considerations and preceding obser-
vations, but without evidence for the effectiveness of such
“best guess” strategies. Moreover, these ad hoc strategies
were adjusted to new observations [39] made during the
outbreak. Thus, individual medical centers used varying
therapeutic regimens [17••], including plasmapheresis,
glucocorticoids, and the anti-C5 monoclonal antibody
eculizumab.
The use of plasmapheresis was based on observations
from the Scotland outbreak in 1996, with 24 adult
patients suffering from HUS [40]. In a multicenter
case–control analysis of the 2011 German outbreak with
STEC O104:H4, no short term benefit for plasmaphere-
sis with or without additional application of glucocorti-
coids was found in 251 patients receiving plasmapheresis, as
compared with 47 patients without plasma exchange [17••]. In
an additional single-center analysis of 130 HUS patients,
again no benefit of plasmaphesesis was observed [36], where-
as the risk of severe AKI and neurological complication was
increased [36]. Likewise, analysis of 90 children with HUS
caused by STEC O104:H4 did not justify recommending
plasma exchange in pediatric HUS [41]. This is in accordance
with a recent prospective follow-up study of 274 children
showing that plasma exchange therapy was associated with a
poor long-term outcome for children with STEC-HUS [42].
Unfortunately, most of these studies are limited by their retro-
spective character and biased by indication, since sicker
patients were more often treated with plasmapheresis. Taken
together, the relevance for plasma exchange therapy in STEC-
HUS is highly questionable and might even be adverse.
A small group of 12 patients with severe neurological
complications were enrolled in a non-controlled trial with
immunoadsorption therapy [43] after several other interven-
tions were assumed to be ineffective. This included multiple
plasmapheresis sessions and/or eculizumab application. On-
ly 2 patients proceeded directly to immunoadsorption.
Hence, the authors stated that antibodies could play a role
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in the pathogenesis of neurological disorders and that immu-
noadsorption might amend the neurological symptoms. This
study is limited by very heterogeneous treatment procedures
and a very small sample size.
At the end of May 2011, a case series of three children
suffering from STEC-HUS was published reporting rapid
clinical improvement under therapy with eculizumab [39].
Therefore, starting from the end of May, over 300 patients of
the German outbreak were treated with eculizumab off-label,
initially as a compassionate use trial that was transformed to a
nonrandomized trial including 198 patients. Final evaluation
of this trial is pending. A short-term outcome analysis of 67
patients treated with eculizumab outside the above-mentioned
trial showed no significant therapeutic benefit, as compared
with a matched control group not having received eculizumab
[17••]. However, in many medical centers, eculizumab was
administered only to patients who had no clinical improve-
ment during plasmapheresis and/or were suffering from severe
neurological complications, which might imply a selection
bias. Therefore, no definite conclusions can be drawn
concerning the effect of eculizumab on the course of HUS.
However, the treatment with eculizumab can be considered as
a save intervention, and therefore, its prognostic impact, as
well as optimal time-point and dosage, should be evaluated in
future prospective randomized trials.
A major issue discussed during the outbreak was the
question of whether or not antibiotics should be used. In
previous retrospective analyses of STEC outbreaks and spo-
radic infections, patients treated with antibiotics were found
to have an increased risk of HUS development [32, 44]. This
dogma was recently confirmed by a large multicenter trial
investigating risk factors for the development of HUS in
EHEC O157:H7 infected children [45]. Therefore, the use
of antibiotics was strongly discouraged unless secondary
complications made antibiotic treatment urgent. In our cen-
ter, we strictly abstained from using antibiotics unless it was
unavoidable. However, since the C5a antibody eculizumab
disrupts the complement cascade and, thereby, increases the
risk for bacterial meningitis [46], antibiotic meningitis pro-
phylaxis was mandatory in patients receiving eculizumab.
Because several in vitro studies did not show any induction
but, rather, suppression of Stx expression by azithromycin,
this antibiotic was selected for recommendation by the Ger-
man Society of Nephrology in the ad hoc guidelines for
meningitis prophylaxis to be given orally for 14 days [38].
The close monitoring of STEC-shedding in stool samples
revealed that all patients receiving azithromycin were rapidly
decolonized from the outbreak strain, while untreated
patients remained positive for STEC significantly longer
[27••]. In detail, among antibiotic-treated patients, long-term
STEC carriage (>28 days) was observed in 1 of 22 patients
(4.5 %; 95 % CI, 0 %–13.3 %), as compared with 35 of 43
patients (81.4 %; 95 % CI, 69.8 %–93.0 %) who were not
treated with antibiotics (p<.001). All 22 patients receiving
azithromycin had at least 3 STEC-negative stool specimens
after the completion of treatment, and no recurrence of STEC
was observed. Therefore, as a proof of principle, a 3-day
course of oral azithromycin was offered as decolonization
therapy to long-term carriers (>28 days) of STEC O104:H4
who were initially not treated with antibiotics, if they were
restricted in their social or working life (e.g., ban from work).
All 15 patients treated with azithromycin for STEC decoloni-
zation had negative stool specimens after the 3-day course,
without any deterioration of renal function or development of
other HUS-related symptoms [27••]. Therefore, successful
decolonization treatment was extended to more than 40
patients, without any adverse effects until now (unpublished
data). Such decolonization regimen has always to be weighed
cautiously against the risk of other potential, pathogen-
independent adverse drug side effects [47].
The in vitro finding that azithromycin does not induce Stx
expression was confirmed recently for STEC O104:H4 by
Bielaszewska et al. [48•]. Comparing the effect of subinhibito-
ry concentrations of several antibiotics on the induction of Stx
production of STEC O104:H4, they found that ciprofloxacin
increased Stx production, while meropenem, rifaximin, tigecy-
cline, and azithromycin did not [48•]. Interestingly, STEC
O104:H4 appears to respond differently to antibiotics, as com-
pared with the “classical” STEC strains O157:H7 [49]. In the
situation of acute STEC disease, the differential response of
various STEC strains to antibiotics requires an early evaluation
of these interactions in order to enable precise warnings or
recommendations concerning antibiotic treatment.
Despite the in vitro induction of Shiga toxin expression by
quinolones, preemptive therapy of STEC-HUS patients with a
combination therapy of meropenem and ciprofloxacin in one
other medical center resulted in statistically significant reduc-
tion of death, seizures, and STEC shedding [17••].
However, it has to be taken into account that all promis-
ing results concerning the use of antibiotics for the treatment
of STEC during the German STEC O104:H4 outbreak were
retrieved either in patients suffering already from HUS or in
clinically recovered, now asymptomatic long-term carriers
with a shedding time of at least 28 days. Therefore, at
present, no definite conclusions can be drawn for the use
of antibiotics in acute STEC diarrhea. Future trials might
further elucidate the pros and cons of this issue. Any anti-
biotics should be handled cautiously in patients with acute
bloody diarrhea caused by STEC until their benefit is ap-
proved in controlled trials.
Conclusion
During the Northern German outbreak of STEC O104:H4 in
2011, new aspects regarding the therapy of STEC infections
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and HUS were investigated retrospectively, raising new
questions that still need to be answered for STEC dis-
ease in general. From a clinical point of view, novel
treatment strategies like eculizumab need further pro-
spective evaluation. The use of plasma exchange thera-
py in STEC-HUS can be regarded as obsolete. The
previous dogma that antibiotics are absolutely contra-
indicated in STEC disease needs to be revised. Espe-
cially in patients with already established HUS, as well
as in long-term STEC carriers who have recovered from
their acute gastrointestinal manifestation, treatment with
azithromycin has a beneficial effect on STEC decoloni-
zation. However, there is no approved indication for
antibiotic treatment during the acute STEC-related bloody
diarrhea. New diagnostic methods for immediate serotyp-
ing, as well as rapid analysis of phage induction and
modulation of Shiga toxin expression by different antibiot-
ics, are essential for clinical decision making (e.g., antibiotic
therapy) in future STEC infections.
Disclosure No potential conflicts of interest relevant to this article
were reported.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Karmali MA, Petric M, Lim C, Fleming PC, Steele BT. Escherichia
coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic
colitis. Lancet. 1983;2:1299–300.
2. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of
haemolytic-uraemic syndrome associated with faecal cytotoxin
and cytotoxin-producing Escherichia coli in stools. Lancet.
1983;1:619–20.
3. Chattaway MA, Dallman T, Okeke IN, Wain J. Enteroaggregative
E. coli O104 from an outbreak of HUS in Germany 2011, could it
happen again? J Infect Dev Ctries. 2011;5:425–36.
4. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat
Rev Microbiol. 2004;2:123–40.
5. Scheutz F, Teel LD, Beutin L, Pierard D, Buvens G, Karch H, et al.
Multicenter evaluation of a sequence-based protocol for subtyping
shiga toxins and standardizing stx nomenclature. J Clin Microbiol.
2012;50:2951–63.
6. Karmali MA, Mascarenhas M, Shen S, Ziebell K, Johnson S,
Reid-Smith R, et al. Association of genomic O island 122 of
Escherichia coliEDL 933with verocytotoxin-producingEscherichia
coli seropathotypes that are linked to epidemic and/or serious disease.
J Clin Microbiol. 2003;41:4930–40.
7. Beutin L, Zimmermann S, Gleier K. Human infections with Shiga
toxin-producing Escherichia coli other than serogroup O157 in
Germany. Emerg Infect Dis. 1998;4:635–9.
8. Goldwater PN, Bettelheim KA. Treatment of enterohemorrhagic
Escherichia coli (EHEC) infection and hemolytic uremic syndrome
(HUS). BMC Med. 2012;10:12.
9. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing
Escherichia coli and haemolytic uraemic syndrome. Lancet.
2005;365:1073–86.
10. Johnson KE, Thorpe CM, Sears CL. The emerging clinical impor-
tance of non-O157 Shiga toxin-producing Escherichia coli. Clin
Infect Dis. 2006;43:1587–95.
11. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl
LB. Clinical course and the role of shiga toxin-producing Escherichia
coli infection in the hemolytic-uremic syndrome in pediatric patients,
1997–2000, in Germany and Austria: a prospective study. J Infect
Dis. 2002;186:493–500.
12. Robert Koch Institut: EHEC-Erkrankungen. In Infektionsepide-
miologisches Jahrbuch meldepflichtiger Krankheiten für 2010.
Edited by Robert Koch Institut (RKI). Berlin; 2011.80–84.
13. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der
Heiden M, et al. Epidemic profile of Shiga-toxin-producing
Escherichia coli O104:H4 outbreak in Germany. N Engl J Med.
2011;365:1771–80.
14. • Robert Koch Institut: Report: Final evaluation and presentation
of epidemiological findings of the EHEC O104:H4 outbreak, Ger-
many 2011. Edited by RKI Department for Infectious Disease
Epidemiology Division 35. Berlin: RKI-Print Shop; 2011. p.
2011. This report provides a complete overview of the epidemiol-
ogy of the STEC O104:H4 outbreak in Germany while also de-
scribing the efforts of the Robert Koch institute in tracing the
outbreak source.
15. Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C,
Wilking H, et al. German outbreak of Escherichia coli O104:H4
associated with sprouts. N Engl J Med. 2011;365:1763–70.
16. King LA, Nogareda F, Weill FX, Mariani-Kurkdjian P, Loukiadis
E, Gault G, et al. Outbreak of Shiga toxin-producing Escherichia
coli O104:H4 associated with organic fenugreek sprouts, France,
June 2011. Clin Infect Dis. 2012;54:1588–94.
17. ••Menne J,NitschkeM, StingeleR,Abu-TairM,Beneke J, Bramstedt J,
et al. Validation of treatment strategies for enterohaemorrhagic Escher-
ichia coliO104:H4 induced haemolytic uraemic syndrome: case–control
study. BMJ. 2012;345:e4565.Thismulticentre retrospective case-control
study of 298 patients with STEC O104:H4 induced HUS shows no
benefit of either plasmapheresis or eculizumab treatment on short term
outcome, on which there is otherwise very limited data.
18. Magnus T, Röther J, Simova O, Meier-Cillien M, Repenthin J,
Möller F, et al. The neurological syndrome in adults during the
2011 northern German E. coli serotype O104:H4 outbreak. Brain.
2012;135:1850–9.
19. Bell BP, Goldoft M, Griffin PM, Davis MA, Gordon DC, Tarr PI,
et al. A multistate outbreak of Escherichia coli O157:H7-associated
bloody diarrhea and hemolytic uremic syndrome from hamburgers.
The Washington experience. JAMA. 1994;272:1349–53.
20. • Bielaszewska M, Mellmann A, Zhang W, Köck R, Fruth A,
Bauwens A, et al. Characterisation of the Escherichia coli strain
associated with an outbreak of haemolytic uraemic syndrome in
Germany, 2011: a microbiological study. Lancet Infect Dis.
2011;11:671–6. This study describes the “intermediate” virulence
profile of STEC O104:H4 and the development of a multiplex PCR
targeting characteristic genes of the outbreak strain.
21. Scheutz F, Moller NE, Frimomodt-Moller J, Boisen N, Morabito S,
Tozzoli R, et al. Characteristics of the enteroaggregative Shiga
8 Curr Infect Dis Rep (2013) 15:4–9
toxin/verotoxin-producing Escherichia coli O104:H4 strain caus-
ing the outbreak of haemolytic uraemic syndrome in Germany.
Euro Surveill. 2011;16:19889.
22. Rohde H, Qin J, Cui Y, Li D, Loman NJ, Hentschke M, et al.
Open-source genomic analysis of Shiga-toxin-producing E. coli
O104:H4. N Engl J Med. 2011;365:718–24.
23. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F,
et al. Origins of the E. coli strain causing an outbreak of hemolytic-
uremic syndrome in Germany. N Engl J Med. 2011;365:709–17.
24. Mellmann A, Harmsen D, Cummings CA, Zentz EB, Leopold SR,
Rico A, et al. Prospective genomic characterization of the German
enterohemorrhagic Escherichia coliO104:H4 outbreak by rapid next
generation sequencing technology. PLoS One. 2011;6:e22751.
25. Laing CR, Zhang Y, Gilmour MW, Allen V, Johnson R, Thomas JE,
et al. A comparison of Shiga-toxin 2 bacteriophage from classical
enterohemorrhagic Escherichia coli serotypes and the GermanE. coli
O104:H4 outbreak strain. PLoS One. 2012;7:e37362.
26. Karch H, Denamur E, Dobrindt U, Finlay BB, Hengge R, Johannes L,
et al. The enemy within us: lessons from the 2011 European Escher-
ichia coli O104:H4 outbreak. EMBO Mol Med. 2012;4:841–8.
27. •• Nitschke M, Sayk F, Härtel C, Roseland RT, Hauswaldt S,
Steinhoff J, et al. Association between azithromycin therapy
and duration of bacterial shedding among patients with Shiga
toxin-producing enteroaggregative Escherichia coli O104:H4.
JAMA. 2012;307:1046–52. This study involving 65 STEC
O104:H4 infected patients with or without HUS shows treat-
ment with azithromycin to dramatically decrease the duration
of STEC shedding without adverse effects, thereby challenging
the absolute contraindication for antibiotics in any stage of
STEC disease.
28. Karch H, Russmann H, Schmidt H, Schwarzkopf A, Heesemann J.
Long-term shedding and clonal turnover of enterohemorrhagic
Escherichia coli O157 in diarrheal diseases. J Clin Microbiol.
1995;33:1602–5.
29. Taormina PJ, Beuchat LR, Slutsker L. Infections associated with
eating seed sprouts: an international concern. Emerg Infect Dis.
1999;5:626–34.
30. Michino H, Araki K, Minami S, Takaya S, Sakai N, Miyazaki M,
et al. Massive outbreak of Escherichia coli O157:H7 infection in
schoolchildren in Sakai City, Japan, associated with consumption
of white radish sprouts. Am J Epidemiol. 1999;150:787–96.
31. Wood R, Donaghy M, Dundas S. Monitoring patients in the
community with suspected Escherichia coli O157 infection during
a large outbreak in Scotland in 1996. Epidemiol Infect. 2001;
127:413–20.
32. Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK,
Hutchinson SJ. The central Scotland Escherichia coli O157:H7
outbreak: risk factors for the hemolytic uremic syndrome and death
among hospitalized patients. Clin Infect Dis. 2001;33:923–31.
33. Piercefield EW, Bradley KK, Coffman RL, Mallonee SM. Hemo-
lytic Uremic Syndrome After an Escherichia coli O111 Outbreak.
Arch Intern Med. 2010;170:1656–63.
34. Boudailliez B, Berquin P, Mariani-Kurkdjian P, Ilef D, Cuvelier B,
Capek I, et al. Possible person-to-person transmission of Escherichia
coli O111–associated hemolytic uremic syndrome. Pediatr Nephrol.
1997;11:36–9.
35. Morabito S, Karch H, Mariani-Kurkdjian P, Schmidt H, Minelli F,
Bingen E, et al. Enteroaggregative, Shiga toxin-producing
Escherichia coli O111:H2 associated with an outbreak of
hemolytic-uremic syndrome. J Clin Microbiol. 1998;36:840–2.
36. Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neuro-
logical involvement in typical Shiga toxin-associated HUS. Nat
Rev Nephrol. 2012. doi: 10.1038/nrneph.2012.196.
37. Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC. Interven-
tions for haemolytic uraemic syndrome and thrombotic thrombocy-
topenic purpura. Cochrane Database Syst Rev. 2009. CD003595.
38. German Society of Nephrology. Advice of the German Soci-
ety of Nephrology on the use of Eculizumab during the 2011
EHEC HUS outbreak, 04.06.2011. http://www.dgfn.eu/aktuell/
ehec-informationen/fuer-das-fachpublikum/advice-on-the-use-
of-ecilizumab.html. 2011.
39. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T,
Kirschfink M, Oualha M, et al. Eculizumab in severe Shiga-toxin-
associated HUS. N Engl J Med. 2011;364:2561–3.
40. Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd
WT. Effectiveness of therapeutic plasma exchange in the 1996
Lanarkshire Escherichia coli O157:H7 outbreak. Lancet. 1999;354:
1327–30.
41. Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Härtel C, et al.
An Outbreak of Shiga Toxin-Producing Escherichia coli O104:H4
Hemolytic Uremic Syndrome in Germany: Presentation and Short-
term Outcome in Children. Clin Infect Dis. 2012;55:753–9.
42. Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M,
Giner T, et al. Need for long-term follow-up in enterohemorrhagic
Escherichia coli-associated hemolytic uremic syndrome due to
late-emerging sequelae. Clin Infect Dis. 2012;54:1413–21.
43. Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, Fiene M,
et al. Treatment of severe neurological deficits with IgG depletion
through immunoadsorption in patients with Escherichia coli O104:
H4-associated haemolytic uraemic syndrome: a prospective trial.
Lancet. 2011;378:1166–73.
44. Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg
CW. Antibiotic treatment of Escherichia coli O157 infection and the
risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J.
2012;31:37–41.
45. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster
DR, et al. Risk factors for the hemolytic uremic syndrome in
children infected with Escherichia coli O157:H7: a multivariable
analysis. Clin Infect Dis. 2012;55:33–41.
46. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria.
Lancet. 2009;373:759–67.
47. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper Jr JA,
Criner GJ, et al. Azithromycin for prevention of exacerbations of
COPD. N Engl J Med. 2011;365:689–98.
48. • Bielaszewska M, Idelevich EA, Zhang W, Bauwens A,
Schaumburg F, Mellmann A, et al. Effects of antibiotics on Shiga
toxin 2 production and bacteriophage induction by epidemic Escher-
ichia coli O104:H4 strain. Antimicrob Agents Chemother. 2012;
56:3277–82. This study examines the effect of different antibiotics
on Stx-harbouring phage induction in STEC O104:H4 in vitro in
order to predict their potential benefit or harm to STEC infected
patients.
49. Corogeanu D, Willmes R, Wolke M, Plum G, Utermöhlen O,
Krönke M. Therapeutic concentrations of antibiotics inhibit Shiga
toxin release from enterohemorrhagic E. coli O104:H4 from the
2011 German outbreak. BMC Microbiol. 2012;12:160.
Curr Infect Dis Rep (2013) 15:4–9 9
